Captor Therapeutics S.A. (CTX) - Total Liabilities
Based on the latest financial reports, Captor Therapeutics S.A. (CTX) has total liabilities worth zł11.27 Million PLN (≈ $3.10 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Captor Therapeutics S.A. - Total Liabilities Trend (2017–2024)
This chart illustrates how Captor Therapeutics S.A.'s total liabilities have evolved over time, based on quarterly financial data. See working capital position of Captor Therapeutics S.A. to evaluate short-term liquidity relative to the company's equity base.
Captor Therapeutics S.A. Competitors by Total Liabilities
The table below lists competitors of Captor Therapeutics S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GOLCONDA GOLD LTD
F:Y87
|
Germany | €15.40 Million |
|
ABOV Semiconductor Co. Ltd
KQ:102120
|
Korea | ₩132.48 Billion |
|
Kc Cottrell
KO:119650
|
Korea | ₩191.66 Billion |
|
Roots Corp
TO:ROOT
|
Canada | CA$159.59 Million |
|
Cantor Equity Partners, Inc. Class A Ordinary Shares
NASDAQ:CEP
|
USA | $108.82 Million |
|
Chien Shing Harbour Service Co Ltd
TW:8367
|
Taiwan | NT$13.30 Billion |
|
Lan Fa Textile Co Ltd
TW:1459
|
Taiwan | NT$1.16 Billion |
|
Eco World International Bhd
KLSE:5283
|
Malaysia | RM111.70 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Captor Therapeutics S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Captor Therapeutics S.A. market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Captor Therapeutics S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Captor Therapeutics S.A. (2017–2024)
The table below shows the annual total liabilities of Captor Therapeutics S.A. from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł23.02 Million ≈ $6.34 Million |
-17.99% |
| 2023-12-31 | zł28.07 Million ≈ $7.73 Million |
+68.33% |
| 2022-12-31 | zł16.68 Million ≈ $4.59 Million |
-13.76% |
| 2021-12-31 | zł19.34 Million ≈ $5.32 Million |
-27.79% |
| 2020-12-31 | zł26.78 Million ≈ $7.37 Million |
+27.42% |
| 2019-12-31 | zł21.02 Million ≈ $5.79 Million |
+43.68% |
| 2018-12-31 | zł14.63 Million ≈ $4.03 Million |
+193.78% |
| 2017-12-31 | zł4.98 Million ≈ $1.37 Million |
-- |
About Captor Therapeutics S.A.
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage. … Read more